# EDGAR Filing Document

**Accession Number:** 0001624326
**File Stem:** 0001094891-26-000053
**Filing Date:** 2026-2
**Character Count:** 13537
**Document Hash:** 41d8cba9b26a5653dbd85d0eb99ec3af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001094891-26-000053.hdr.sgml**: 20260209

**ACCESSION NUMBER**: 0001094891-26-000053

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260209

**DATE AS OF CHANGE**: 20260209

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lucid Diagnostics Inc.
- **CENTRAL INDEX KEY:** 0001799011
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 825488042
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92965
- **FILM NUMBER:** 26612925

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212 949 4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAVmed Inc.
- **CENTRAL INDEX KEY:** 0001624326
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471214177
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (212) 949-4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAXmed Inc.
- **DATE OF NAME CHANGE:** 20141105

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**Lucid Diagnostics Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**54948X109**

*(CUSIP Number)*

**Lishan Aklog, M.D.**<br>360 MADISON AVENUE<br>25TH FLOOR<br>NEW YORK NY 10017<br>917-813-1828

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/03/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **54948X109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PAVmed Inc.** | Name of reporting person<br>**PAVmed Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**38816903.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**31302444.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**38816903.00** | Aggregate amount beneficially owned by each reporting person<br>**38816903.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**27.5%** | Percent of class represented by amount in Row (11)<br>**27.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Lucid Diagnostics Inc.

**(c) Address of Issuer's Principal Executive Offices:**
360 MADISON AVENUE, 360 MADISON AVENUE, NEW YORK, NY, 10017

This Amendment No. 6 (this "Amendment") to the Schedule 13D that was originally filed on October 27, 2021 and was previously amended on December 2, 2022, February 2, 2024, February 20, 2024, December 12, 2024 and October 10, 2025 (as amended to date, this "Schedule 13D"), is filed on behalf of PAVmed Inc., a Delaware corporation (the "Reporting Person"), with respect to the common stock, par value $0.001 per share ("Common Stock"), of Lucid Diagnostics Inc. (the "Issuer"). Except as modified or supplemented by this Amendment, the Schedule 13D as in effect prior to this Amendment remains unchanged. Capitalized terms used but not defined in this Amendment have the meanings ascribed to them in the Schedule 13D as in effect prior to this Amendment.

**Item 4. Purpose of Transaction**

The Reporting Person is the parent company of the Issuer. As a result of its ability to vote 27.5% of the Common Stock (and an estimated 26.3% of all the capital stock of the Issuer), the Reporting Person has the power to significantly influence the election of directors and all other matters that would require the vote of the outstanding shares of capital stock of the Issuer. Subject to the restrictions on transfer described in Item 6, the Reporting Person or any of the Principals, respectively, may acquire additional securities of the Issuer and may sell all or a portion of the securities then held in the open market or in privately negotiated transactions, although none of the Reporting Person or the Principals has any present intention to acquire or sell any securities of the Issuer except as described in Item 6 (including pursuant to the Amendment Agreement described in such item). Each of the Reporting Person and each of the Principals, respectively, intends to review its ownership of the Issuer on a continuing basis. Any actions the Reporting Person or any Principal might undertake with respect to the Common Stock may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments relating to the Reporting Person, the Principals and/or the Issuer.

Other than as described above, and except in accordance with the Reporting Person's role as the parent company of the Issuer and the Principals' roles as officers and directors of the Reporting Person and the Issuer, the Reporting Person and Principals do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Reporting Person:
38,816,903 shares, 27.5%

Lishan Aklog, M.D., Chairman of the Board and Chief Executive Officer of the Reporting Person:
1,541,627 shares, 1.1%

Dennis McGrath,  President and Chief Financial Officer of the Reporting Person:
1,393,569 shares, 1.0%

Shaun O'Neil, Chief Operating Officer of the Reporting Person:
876,763 shares, 0.6%

Michael Gordon, General Counsel of the Reporting Person:
900,000 shares, 0.6%

Michael Glennon, Director of the Reporting Person:
422,432 shares, 0.3%

Sundeep Agrawal, M.D., Director of the Reporting Person:
0 shares, 0.0%

Timothy Baxter, Director of the Reporting Person:
0 shares, 0.0%

Ronald Sparks, Director of the Reporting Person:
543,960 shares, 0.4%

Debra White, Director of the Reporting Person:
480,300 shares, 0.3%

**(b)**
Reporting Person:
Sole voting power: 38,816,903 shares
Sole dispositive power: 31,302,444 shares
Shared voting and dispositive power: 0 shares

Dr. Aklog:
Sole voting power: 0 shares
Sole dispositive power: 1,541,627 shares
Shared voting and dispositive power: 0 shares

Mr. McGrath:
Sole voting power: 0 shares
Sole dispositive power: 1,393,569 shares
Shared voting and dispositive power: 0 shares

Mr. O'Neil:
Sole voting power: 0 shares
Sole dispositive power: 876,763 shares
Shared voting and dispositive power: 0 shares

Mr. Gordon:
Sole voting power: 0 shares
Sole dispositive power: 900,000 shares
Shared voting and dispositive power: 0 shares

Mr. Glennon:
Sole voting and dispositive power: 422,432 shares
Shared voting and dispositive power: 0 shares

Dr. Agrawal:
Sole voting and dispositive power: 0 shares
Shared voting and dispositive power: 0 shares

Mr. Baxter:
Sole voting and dispositive power: 0 shares
Shared voting and dispositive power: 0 shares

Mr. Sparks:
Sole voting and dispositive power: 543,960 shares
Shared voting and dispositive power: 0 shares

Ms. White:
Sole voting and dispositive power: 480,300 shares
Shared voting and dispositive power: 0 shares

**(c)**
None, except as described in Item 6 below.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The Reporting Person entered into an Amendment Agreement, dated February 3, 2026 (the "Amendment Agreement"), with the holder (the "Holder") of the amended and restated senior secured convertible promissory note issued by the Reporting Person to the Holder on February 3, 2026 (the "2026 Note"). Under the Amendment Agreement, among other things, the Reporting Person granted the Holder the right to receive from the Reporting Person 300,000 shares of Issuer's common stock (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), upon the earliest of (x) February 3, 2029, the maturity date of the 2026 Note, (y) the date the 2026 Note no longer remains outstanding and (z) such earlier date as the Reporting Person shall notify the Holder in writing, subject to the beneficial ownership limitation described in the Amendment Agreement.

The Reporting Person entered into an agreement, dated as of October 9, 2025 ("Voting Agreement"), with a stockholder of the Issuer, pursuant to which such stockholder granted the Reporting Person a voting proxy over the shares of the Issuer's capital stock owned by such person, covering shares of Common Stock representing 3,177,500 votes and other shares of capital stock representing 4,063,286 votes. The Reporting Person previously entered into voting agreements with certain of the officers of the Issuer, covering shares of Common Stock representing 4,336,959 votes.

The Reporting Person also is party to (i) a security and pledge agreement with the Holder, dated as of April 4, 2022 (the "Security and Pledge Agreement"), (ii) a management services agreement with the Issuer, dated as of May 12, 2018, as amended from time to time (the "MSA"), and (iii) a payroll and benefit expense reimbursement agreement with the Issuer, dated as of November 30, 2022, as amended from time to time (the "PBERA"), each of which contain obligations relating to the acquisition, transfer or voting of the Common Stock. In addition, the Reporting Person undertook certain voting obligations in connection with the sale by the Issuer of convertible notes pursuant to a securities purchase agreement, dated as of November 12, 2024 (the "Issuer Note SPA"). The Security and Pledge Agreement is described in the Reporting Person's Current Report on Form 8-K filed on April 4, 2022, the MSA and PBERA are described in the Issuer's Annual Report on Form 10-K filed on March 24, 2025, and the obligations in connection with the Issuer Note SPA are described in Amendment No. 4 to this Schedule 13D filed on December 12, 2024, and such descriptions are incorporated herein by reference.

Certain of the Principals have been granted restricted stock and/or stock option awards as compensation by the Issuer, which awards provide for the acquisition of Common Stock in the case of the options, and which awards are subject to vesting and restrictions on transfer, all pursuant to the applicable award agreement.

The foregoing summaries of the Voting Agreements, Security and Pledge Agreement, MSA, PBERA and Amendment Agreement are qualified in their entirety by reference to the full text of the agreements, which are attached or incorporated by reference as Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PAVmed Inc.

**Signature:** /s/ Lishan Aklog, M.D.

**Name/Title:** Lishan Aklog, M.D.

**Date:** 02/09/2026